Trans-(1S,3S)-3-[[5-amino-2-(4-fluoropyrazol-1-yl)thieno[3,2-b]pyridin-7-yl]amino]cyclopentan-1-ol
C15H16FN5OS — CID 162785030
Data last refreshed: (MolForge compound catalog, from PubChem)
About Trans-(1S,3S)-3-[[5-amino-2-(4-fluoropyrazol-1-yl)thieno[3,2-b]pyridin-7-yl]amino]cyclopentan-1-ol
Trans-(1S,3S)-3-[[5-amino-2-(4-fluoropyrazol-1-yl)thieno[3,2-b]pyridin-7-yl]amino]cyclopentan-1-ol (PubChem CID 162785030) has the molecular formula C15H16FN5OS and a molecular weight of 333.39 g/mol. Its IUPAC name is trans-(1S,3S)-3-[[5-amino-2-(4-fluoropyrazol-1-yl)thieno[3,2-b]pyridin-7-yl]amino]cyclopentan-1-ol.
Molecular Properties
| Compound Name | Trans-(1S,3S)-3-[[5-amino-2-(4-fluoropyrazol-1-yl)thieno[3,2-b]pyridin-7-yl]amino]cyclopentan-1-ol |
|---|---|
| PubChem CID | 162785030 |
| Molecular Formula | C15H16FN5OS |
| Molecular Weight | 333.39 g/mol |
| Exact Mass | 333.11 |
| IUPAC Name | trans-(1S,3S)-3-[[5-amino-2-(4-fluoropyrazol-1-yl)thieno[3,2-b]pyridin-7-yl]amino]cyclopentan-1-ol |
| SMILES | Nc1cc(N[C@H]2CC[C@H](O)C2)c2sc(-n3cc(F)cn3)cc2n1 |
| InChI | InChI=1S/C15H16FN5OS/c16-8-6-18-21(7-8)14-5-12-15(23-14)11(4-13(17)20-12)19-9-1-2-10(22)3-9/h4-7,9-10,22H,1-3H2,(H3,17,19,20)/t9-,10-/m0/s1 |
| InChIKey | CQSFJCFBHCGISS-UWVGGRQHSA-N |
| XLogP | 2.53 |
| TPSA | 88.99 Ų |
| H-Bond Donors | 3 |
| H-Bond Acceptors | 7 |
| Rotatable Bonds | 3 |
| Heavy Atoms | 23 |
| Complexity | — |
Lipinski Rule of Five
Passes Rule of Five
| Rule | Value |
|---|---|
| MW ≤ 500 | 333.39 |
| LogP ≤ 5 | 2.53 |
| H-Bond Donors ≤ 5 | 3 |
| H-Bond Acceptors ≤ 10 | 7 |
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 162785030 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.